Methylene Blue
Methylthioninium chloride · MB · USP methylene blue
Cognitive benefit in humans at 260–280 mg single doses (Rodriguez/Telch 2017)
Overview
Methylene blue (methylthioninium chloride) is a synthetic phenothiazine dye in clinical use since the late nineteenth century, making it one of the oldest drugs still in the formulary. Its approved role is as a reducing agent that reverses methemoglobinemia, but its redox chemistry — the ability to cycle between oxidized (blue) and reduced (colorless) forms — also underlies a growing research interest in it as a low-dose mitochondrial and cognitive agent.
The cognitive interest rests on a genuine, if small, human literature. Functional-MRI studies in healthy adults using single oral doses of roughly 260–280 mg (about 4 mg/kg) reported increased task-evoked activity in memory- and attention-related networks and improved short-term recall, and a separate trial found enhanced fear-extinction memory at 260 mg. Animal work established a hormetic (inverted-U) dose-response: low doses of 0.5–4 mg/kg enhance cytochrome-c-oxidase activity and learning, whereas doses above roughly 10 mg/kg lose the benefit and can act as a pro-oxidant.
Two features dominate practical use. First, dosing is non-linear: more is not better, and the high single doses used in imaging studies are not the same as a daily regimen. Community low-dose use therefore clusters far lower, around 5–20 mg per day, although no standardized supplement dose is established. Second, methylene blue is a potent monoamine-oxidase inhibitor, so combining it with serotonergic drugs carries a real risk of serotonin syndrome. Figures here are summarized for research reference only.
Key parameters
- Dose range
- Low-dose ~5–20 mg/day (community); 0.5–4 mg/kg single dose (research)
- Frequency
- Daily (low-dose) — morning/early afternoon
- Half-life
- Long, ~15 hours; cleared over roughly a day, mostly in urine
- Route
- Oral (also 1 mg/kg IV for methemoglobinemia)
- Vial sizes
- —
- Regulatory status
- FDA-approved as a drug for methemoglobinemia and used in other clinical and diagnostic settings (e.g. surgical staining). Low-dose 'nootropic' or longevity use is off-label and not an approved indication; only pharmaceutical-grade (USP) material is appropriate for ingestion.
Mechanism of action
Mitochondrial electron cycling (cytochrome-c oxidase)
At low concentrations methylene blue accepts and donates electrons within the electron-transport chain, effectively bypassing complex I/III bottlenecks and increasing cytochrome-c-oxidase (complex IV) activity, which is coupled to greater oxygen consumption and ATP production.
Monoamine oxidase-A inhibition
It is a potent reversible inhibitor of MAO-A, raising synaptic serotonin and other monoamines. This contributes to mood/cognitive effects but is also the basis of its serotonin-syndrome interaction risk with SSRIs, SNRIs, and MAOIs.
Antioxidant / nitric-oxide modulation
By reducing superoxide generation and inhibiting nitric oxide synthase and soluble guanylate cyclase, it can lower certain forms of oxidative and nitrosative stress at low doses — an effect that reverses at higher concentrations, where it becomes pro-oxidant.
Tau / amyloid aggregation effects
Methylthioninium has been studied as an inhibitor of tau protein aggregation (the basis of the derivative drug candidate that reached Alzheimer's trials), though that work concerns a distinct formulation rather than over-the-counter methylene blue.
Dosing protocol & phases
| Phase | Weeks | Dose | Notes |
|---|---|---|---|
| Low-dose (community) | Ongoing | ~5–20 mg orally per day | Often split between morning and early afternoon to avoid sleep disruption; no standardized, FDA-recognized oral supplement dose exists. Pharmaceutical/USP grade only. |
| Research single dose (cognition) | Study sessions only | ~260–280 mg orally (≈4 mg/kg), one time | Doses used in human imaging/memory studies — administered once under monitoring, not as a daily regimen. Do not extrapolate to chronic use. |
| Approved clinical (methemoglobinemia) | Acute | 1 mg/kg slow IV | Distinct approved indication and route, included for context; not a cognitive protocol. |
Supplies needed
Affiliate disclosure: we may earn a commission from supplier links, at no extra cost to you. For research and educational use only.
Recommended supply
Methylene Blue — research vial
From our verified partner Dynotides, with a third-party certificate of analysis per batch.
Injection supplies
- View
Bacteriostatic water
Diluent for reconstituting lyophilized vials.
- Buy
Insulin syringes (U-100)
0.3–0.5 mL, 29–31 G for accurate small draws.
- Buy
Alcohol prep pads
Sterile swabs for the vial stopper and site.
- Buy
Sharps container
Safe disposal of used needles.
- Buy
Storage fridge
Keeps reconstituted vials at 2–8 °C.
- Buy
Insulated travel case
Cooled, TSA-friendly case for travel.
Missed-dose guidance
For off-label low-dose oral use there is no approved cognitive-dosing schedule; a missed dose is simply skipped and the normal routine resumed the next day rather than doubled. Because of the long half-life, taking it late in the day can interfere with sleep.
Side effects & safety
| Category | Effect | Trial incidence |
|---|---|---|
| General | Blue–green discoloration of urine (and sometimes tongue/stool)Expected, harmless pharmacological effect of the dye. | — |
| Drug interaction | Serotonin syndrome with serotonergic agentsMethylene blue is a potent MAO-A inhibitor; concurrent SSRIs/SNRIs/MAOIs can precipitate serotonin syndrome. This is the most important safety consideration. | — |
| Hematologic | Hemolysis in G6PD deficiencyCan trigger hemolytic anemia in G6PD-deficient individuals and is generally contraindicated in them. | — |
| Gastrointestinal | Nausea, diarrhea, abdominal discomfortMore likely at higher oral doses. | — |
| Hematologic | Paradoxical methemoglobinemia at high dosesAbove roughly 7 mg/kg it can cause, rather than treat, methemoglobinemia. | — |
| Dermatologic | PhotosensitivityMethylene blue can be phototoxic; sun exposure caution is advised. | — |
Clinical trials & evidence
Rodriguez et al. — fMRI of attention/memory
Phase 1 (human imaging)Single dose · 26 healthy adults
A single 280 mg oral dose increased functional-MRI responses during sustained-attention and short-term-memory tasks and improved memory retrieval.
Trial identifier needs verification
Telch et al. — fear-extinction memory
RCT (human)Single dose · 42 adults with claustrophobic fear
260 mg given after extinction training enhanced retention of fear extinction in participants who reached low fear during training.
Trial identifier needs verification
Rojas et al. — preclinical dose-response
Preclinical (rodent)Varies · Rats
Established the hormetic curve: 0.5–4 mg/kg enhanced cytochrome-oxidase activity, metabolism, and memory; higher doses lost the effect.
Trial identifier needs verification
Storage & handling
- Lyophilized
- Not a lyophilized peptide. Pharmaceutical methylene blue is supplied as tablets, capsules, or solution — store at room temperature (about 15–30 °C) in a sealed, light-protected container per product labeling.
- Reconstituted
- Liquid/solution formulations should be kept tightly closed and protected from light; follow the manufacturer's expiry. It stains skin, fabric, and surfaces readily.
Comparisons
| Vs. | Target | Half-life | Dosing | Efficacy | Status |
|---|---|---|---|---|---|
| NAD+ | Redox electron cycler vs redox coenzyme | ~15 h vs short | mg oral, hormetic vs tens–hundreds of mg, often IV | Both framed around mitochondrial energetics via different mechanisms | Approved drug (for methemoglobinemia) vs compounded/research for injection |
Sources & references
- [1]Rodriguez P et al. Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology 2016/2017. ↗ source
- [2]Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012. ↗ source
- [3]Telch MJ et al. Use of a brief fear memory reactivation procedure for enhancing exposure therapy (methylene blue). Depress Anxiety 2017. ↗ source
Frequently asked questions
Is methylene blue an approved nootropic?
No. It is an approved drug for methemoglobinemia and is used in other clinical and diagnostic settings, but its low-dose use for cognition or longevity is off-label. The supporting cognitive evidence is limited to a handful of small human studies.
Why does dosing follow an inverted-U curve?
At low concentrations methylene blue behaves as an antioxidant and electron carrier that boosts mitochondrial respiration; at higher concentrations it flips to a pro-oxidant and the cognitive benefit disappears. That is why the research single doses are not simply scaled up for daily use, and why community low-dose use is far smaller.
What is the main safety concern?
Its monoamine-oxidase-inhibiting activity means combining it with serotonergic medications (SSRIs, SNRIs, MAOIs, some others) can cause serotonin syndrome. It can also trigger hemolysis in people with G6PD deficiency. Only pharmaceutical-grade material should ever be ingested.
Related protocols
NAD+
Nicotinamide adenine dinucleotide
Central redox coenzyme; declines with age (mechanistic interest)
Looking to match this protocol to a verified research vial? Our partner supplier publishes a certificate of analysis per batch.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.